<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00841256</url>
  </required_header>
  <id_info>
    <org_study_id>AL0506st</org_study_id>
    <secondary_id>2006-005911-82</secondary_id>
    <nct_id>NCT00841256</nct_id>
  </id_info>
  <brief_title>Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children</brief_title>
  <official_title>... Study to Evaluate Efficacy and Safety of Perennial Sublingual SIT With a Solution of Grass Pollen Allergen ... in Children With Clinically Relevant Grass Pollen Sensitivity in Comparison to a ... Standard Treatment With Add on Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergopharma GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergopharma GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of safety and efficacy of sublingual immunotherapy with grass pollen allergens
      formulated as solution in comparison to a symptomatic standard treatment with add on placebo
      in grass pollen allergic children suffering from allergic rhinitis/rhinoconjunctivitis with
      or without bronchial asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although highly effective, subcutaneous administration of allergens may cause inconvenience
      in some patients. Alternative routes, e.g. nasal and oral, have therefore been investigated
      to find an immunotherapy regimen largely accepted by all groups of patients, including
      children.

      Sublingual specific immunotherapy (SLIT) may represent a more acceptable route of
      immunotherapy. It may be an optimal therapy option especially for children because they often
      fear injections.

      In this study children are to be treated with a preparation of a grass pollen allergen
      extract in a water/glycerol solution with phosphate buffered saline in comparison to a
      symptomatic standard treatment with add on placebo, in order to investigate efficacy and
      safety of the study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Symptom-Medication-Score</measure>
    <time_frame>After 1 year of treatment</time_frame>
    <description>The change of the area under the curve of the symptom and medication score (SMS) from the baseline season to the season after 1 year of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the documentation of adverse events (AEs)</measure>
    <time_frame>Entire treatment period</time_frame>
    <description>Safety of treatments during the entire treatment period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">207</enrollment>
  <condition>Allergic Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>Immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grass pollen allergens in a water/glycerol solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Water/glycerol solution with phosphate buffered saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Grass pollen allergens in a water/glycerol solution</intervention_name>
    <description>In total up to 4 drops (dose for maintenance therapy) are administered under the tongue.</description>
    <arm_group_label>Immunotherapy</arm_group_label>
    <other_name>Allerslit forte grasses</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo was given in the same way as the sublingual active treatment. Symptomatic standard treatment, i.e. antihistamines and glucocorticoids as well as alphamimetics is allowed during grass pollen season.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  4 - &lt;12 years (at the time of inclusion)

          -  Positive SPT

          -  Positive EAST

          -  Positive CPT

        Exclusion Criteria:

          -  Serious chronic diseases

          -  Other perennial allergies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Wahn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Paediatrie Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.allergopharma.de</url>
    <description>Leader in specific allergy research and therapy</description>
  </link>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005911-82/DE</url>
    <description>Click here for information about this trial in the European Clinical Trials Register</description>
  </link>
  <results_reference>
    <citation>Wahn U, Klimek L, Ploszczuk A, Adelt T, Sandner B, Trebas-Pietras E, Eberle P, Bufe A; SLIT Study Group. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study. J Allergy Clin Immunol. 2012 Oct;130(4):886-93.e5. doi: 10.1016/j.jaci.2012.06.047. Epub 2012 Aug 29.</citation>
    <PMID>22939758</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2008</study_first_submitted>
  <study_first_submitted_qc>February 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2009</study_first_posted>
  <last_update_submitted>October 15, 2015</last_update_submitted>
  <last_update_submitted_qc>October 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>specific immunotherapy</keyword>
  <keyword>SIT</keyword>
  <keyword>SLIT</keyword>
  <keyword>sublingual</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Glycerol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

